Bronchogen
Also known as: Lung bioregulator, AEDL
Bronchogen (also called Lung bioregulator or AEDL) is a khavinson bioregulator. Bronchogen is Ala-Glu-Asp-Leu, a synthetic tetrapeptide in the Khavinson bioregulator series associated with bronchial and pulmonary tissue. The proposed mechanism common to that series is that short peptides enter the cell nucleus and interact directly with specific promoter regions of DNA, altering transcription of tissue-relevant genes — a form of peptide-directed epigenetic regulation.
For research use only.
Key Facts
- CAS
- 167174-49-0
- Molecular Weight (MW)
- 391.39 g/mol
- Half-life
- Not established (small tripeptide)
- FDA status
- Not Approved
- Administration Route
- —
- Frequency
- —
- Last updated
- Aug 30, 2026
- Reviewed
- Aug 30, 2026
- Targets
- Bronchial epithelium (proposed)
Vendor price snapshot
Each vendor counts once, at the median price per mg of its own listings; the typical range is the middle half of vendors. From public vendor listings collected between Dec 2025 and Oct 2026, so confirm the live price on the vendor site. Peptide Library does not sell peptides.
- Vendors listing this peptide
- 7
- Listed offers
- 10
- Median price per mg
- $3.15/mg
- Typical $2.75–$4.65/mg
Research summary
Short peptide marketed as a Khavinson bronchial/lung bioregulator (often AEDL). Russian literature only; not FDA-approved.
Peptide Library's Bronchogen profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Protocol
- Dosage Range
- Per research protocol
- Frequency
- —
- Cycle
- —
- Administration Route
- —
- Reconstitution Guide
- —
Not yet checked against primary sources
These figures are compiled from earlier reference material. They have not been verified against FDA labelling, registered trials or published literature, no citation is attached to them, and none of them is a recommended dose. Bronchogen is queued for dosage evidence review.
Compare reported doses across the whole librarySequence & molecular data
| Molecular formula | C14H25N5O7 |
|---|---|
| Molecular weight | 391.39 g/mol |
| CAS number | 167174-49-0 |
| Half-life | Not established (small tripeptide) |
| Appearance | White lyophilized powder |
| Formulation | Lyophilized Powder |
| PubChem CID | 11690869 |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Bronchogen is Ala-Glu-Asp-Leu, a synthetic tetrapeptide in the Khavinson bioregulator series associated with bronchial and pulmonary tissue. The proposed mechanism common to that series is that short peptides enter the cell nucleus and interact directly with specific promoter regions of DNA, altering transcription of tissue-relevant genes — a form of peptide-directed epigenetic regulation. Supporting work consists largely of cytogenetic and cell-culture studies published by one research group, predominantly in Russian-language journals. The mechanism has not been independently established in Western controlled research, and no clinical trials support the tissue-specific claims.
Origin
Synthetic short peptide from the Khavinson bioregulator series.
Targets
Studies
- Effect of the peptide bronchogen (Ala-Asp-Glu-Leu) on DNA thermostability
- [ANTIINFLAMMATORY AND REGENERATIVE EFFECT OF PEPTIDE THERAPY IN THE MODEL OF OBSTRUCTIVE LUNG PATHOLOGY]
- Short Exogenous Peptides Regulate Expression of CLE, KNOX1, and GRF Family Genes in Nicotiana tabacum
- Modulating Effect of Peptide Therapy on the Morphofunctional State of Bronchial Epithelium in Rats with Obstructive Lung Pathology
- Peptides tissue-specifically stimulate cell differentiation during their aging
Regulatory & research status
Bronchogen is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.
| FDA status | Not Approved |
|---|---|
| Availability | Research-Only |
| WADA (sport) | Unknown / Not Listed |
| Library classification | Research-Only |
Benefits
Bronchogen side effects
Side Effects
- Not characterized in modern RCTs
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
Bronchogen: frequently asked questions
What is Bronchogen?
Short peptide marketed as a Khavinson bronchial/lung bioregulator (often AEDL). Russian literature only; not FDA-approved.
How does Bronchogen work?
Bronchogen is Ala-Glu-Asp-Leu, a synthetic tetrapeptide in the Khavinson bioregulator series associated with bronchial and pulmonary tissue. The proposed mechanism common to that series is that short peptides enter the cell nucleus and interact directly with specific promoter regions of DNA, altering transcription of tissue-relevant genes — a form of peptide-directed epigenetic regulation.
Is Bronchogen FDA approved?
No. Bronchogen is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.
What is the half-life of Bronchogen?
Reported half-life for Bronchogen is Not established (small tripeptide). Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.
What peptides are similar to Bronchogen?
Compounds most often compared with Bronchogen include Bonomarlot, Cardiogen, Cartalax and Cerluten. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- Effect of the peptide bronchogen (Ala-Asp-Glu-Leu) on DNA thermostability — Bull Exp Biol Med, 2011External reference
- [ANTIINFLAMMATORY AND REGENERATIVE EFFECT OF PEPTIDE THERAPY IN THE MODEL OF OBSTRUCTIVE LUNG PATHOLOGY] — Ross Fiziol Zh Im I M Sechenova, 2017External reference
- Short Exogenous Peptides Regulate Expression of CLE, KNOX1, and GRF Family Genes in Nicotiana tabacum — Biochemistry (Mosc), 2017External reference
- Modulating Effect of Peptide Therapy on the Morphofunctional State of Bronchial Epithelium in Rats with Obstructive Lung Pathology — Bull Exp Biol Med, 2015External reference
- Peptides tissue-specifically stimulate cell differentiation during their aging — Bull Exp Biol Med, 2012External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Aug 30, 2026 · Version 1
This Bronchogen profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Bronchogen research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →